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Introduction
Radioiodine is a safe and effective treatment for Graves’
disease. Iatrogenic hypothyroidism is very common after
treatment, but its onset is unpredictable. Even a short
episode of hypothyroidism can result in significant mor-
bidity and ideally should be avoided. In Newcastle a
standard dose of radioiodine (400MBq) is used, but for
historical reasons two different protocols are used after
radioiodine: Regimen A: regular clinical and biochemical
monitoring and initiation of levothyroxine when serum
thyroid hormones have normalized, and Regimen B:
block and replace with Carbimazole and levothyroxine
starting 2 weeks post-radioiodine and continuing for 6
months, then withdrawing Carbimazole, but continuing
with levothyroxine long-term.
Methods
The objective was to compare the two protocols for inci-
dence of biochemical and clinical hypothyroidism during a
12 month post-radioiodine follow-up period and effects
on weight gain and development or progression of orbito-
pathy. Patients with Graves’ disease who were treated
between January 2008-December 2009 were included. The
medical records were reviewed and data were collected
and analyzed.
Results
One hundred and twenty two patients were studied, 78
treated with Regimen A and 43 with Regimen B. Euthyroid-
ism at 8 weeks, 6 months and 12 months post-radioiodine
was achieved in 50%, 64% and 73% of patients with Regi-
men A and 65.1%, 71% and 65% in patients with regimen B
respectively. Clinical hypothyroidism during follow-up was
commoner in Regimen A than B (52.6% vs 16.3% respec-
tively, p<0.05). Weight gain was reported more frequently
in Regimen A than B (43.6% vs 20.9%, p<0.05). The inci-
dence of new Graves’ orbitopathy developing after radioio-
dine was higher in Regimen A than B (11.1% vs 5.3%).
Conclusions
A 6 month course of block and replace followed by
levothyroxine after a standard 400MBq dose of radioiodine
is associated with better clinical outcomes than a watchful
approach and initiation of levothyroxine based on bio-
chemical and clinical indicators.
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